Zirconium-89 is a promising radionuclide in the development of new immuno-PET agents for in vivo imaging of cancerous tumours and radioimmunotherapy (RIT) planning. Besides the convenient half-life of 78.4 h, 89Zr has a beta plus emission rate of 23% and a low maximum energy of 0.9 MeV, delivering good spatial resolution as a result of short positron range in tissue (around 1 mm). Cyclotron production for the radiometal of 89Zr was investigated to find optimal conditions according to results of FLUKA code Monte Carlo modelling of irradiation processes, nuclear reactions and target design. This was followed by reasonably detailed experimental validation (making cyclotron productions for expected high product yield and low impurities levels f...
The production and demand for Zirconium-89 (half-life time 78h, Emoy. β+ = 395 keV) continues to gro...
Introduction Zr-89 is a useful radionuclide for radiolabeling proteins and other molecules.1,2 There...
The 89Zr is one of the most promising radionuclide in Nuclear Medicine for labelling monoclonal anti...
Zirconium-89 is a promising radionuclide in the development of new immuno-PET agents for in vivo ima...
Zirconium 89 ($\text{}^{89}Zr$) is a promising radionuclide for development of new PET agents due to...
Zirconium 89 (89Zr) is a promising radionuclide for development of new PET agents due to its conveni...
none8The widely used Monte Carlo simulation code FLUKA has been utilized to prototype a solid target...
The radionuclide zirconium-89 can be employed for the positron emission tomography (PET). In this st...
89Zr (T1/2 = 3.27 d) is an important β+-emitting radionuclide of zirconium used in immuno PET. The e...
The use of radionuclides plays a crucial role in Nuclear Medicine in the areas of diagnostics, of me...
La production et la demande en Zirconium-89 (temps de demi-vie 78h, Emoy. β+ = 395 keV) ne cesse de ...
Zirconium-89 (Zr-89) is an emerging radionuclide for positron emission tomography (PET), with nuclea...
Few PET isotopes are suitable for antibody labelling since immunoPET requires that the PET isotope c...
Zirconium-89 (89Zr, t1/2 = 3.27 days) owns great potential in nuclear medicine, being extensively us...
This article is intended to provide an overview of the production and application of 89Zr for the pr...
The production and demand for Zirconium-89 (half-life time 78h, Emoy. β+ = 395 keV) continues to gro...
Introduction Zr-89 is a useful radionuclide for radiolabeling proteins and other molecules.1,2 There...
The 89Zr is one of the most promising radionuclide in Nuclear Medicine for labelling monoclonal anti...
Zirconium-89 is a promising radionuclide in the development of new immuno-PET agents for in vivo ima...
Zirconium 89 ($\text{}^{89}Zr$) is a promising radionuclide for development of new PET agents due to...
Zirconium 89 (89Zr) is a promising radionuclide for development of new PET agents due to its conveni...
none8The widely used Monte Carlo simulation code FLUKA has been utilized to prototype a solid target...
The radionuclide zirconium-89 can be employed for the positron emission tomography (PET). In this st...
89Zr (T1/2 = 3.27 d) is an important β+-emitting radionuclide of zirconium used in immuno PET. The e...
The use of radionuclides plays a crucial role in Nuclear Medicine in the areas of diagnostics, of me...
La production et la demande en Zirconium-89 (temps de demi-vie 78h, Emoy. β+ = 395 keV) ne cesse de ...
Zirconium-89 (Zr-89) is an emerging radionuclide for positron emission tomography (PET), with nuclea...
Few PET isotopes are suitable for antibody labelling since immunoPET requires that the PET isotope c...
Zirconium-89 (89Zr, t1/2 = 3.27 days) owns great potential in nuclear medicine, being extensively us...
This article is intended to provide an overview of the production and application of 89Zr for the pr...
The production and demand for Zirconium-89 (half-life time 78h, Emoy. β+ = 395 keV) continues to gro...
Introduction Zr-89 is a useful radionuclide for radiolabeling proteins and other molecules.1,2 There...
The 89Zr is one of the most promising radionuclide in Nuclear Medicine for labelling monoclonal anti...